5.0
12. März 2026
Aktueller Mitarbeiter, weniger als 1 Jahr
London, England
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Interesting work with real clinical impact. The team is friendly and supportive, and you get good exposure to sequencing technologies and clinical validation projects. Because the team is small, you can take ownership of projects and contribute ideas.
Kontras
As the company is growing, some processes and documentation are still developing. Priorities can sometimes change quickly and communication between teams could be clearer.